ArticleCurrent transplantation reports2015
Bioreactor Development for Lung Tissue Engineering.
Article in Current transplantation reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Cryopreservation of human lung tissue for 3D ex vivo analysis.Respiratory research · 2025Review
- Microfluidic Systems for Neural Cell Studies.Bioengineering (Basel, Switzerland) · 2023Review
- Bioengineering and Clinical Translation of Human Lung and its Components.Advanced biology · 2023Review
- 3D tissue-engineered lung models to study immune responses following viral infections of the small airways.Stem cell research & therapy · 2022Review
- Emerging Paradigms in Bioengineering the Lungs.Bioengineering (Basel, Switzerland) · 2022Review
- 3D Cell Cultures: Evolution of an Ancient Tool for New Applications.Frontiers in physiology · 2022Review
- Bioartificial lungs based on de- and recellularisation approaches: a historical perspective.Breathe (Sheffield, England) · 2020Article
- Lung Microvascular Niche, Repair, and Engineering.Frontiers in bioengineering and biotechnology · 2020Review
- 3D bioprinting for lungs and hollow organs.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Lung bioengineering: advances and challenges in lung decellularization and recellularization.Current opinion in organ transplantation · 2018Review
- Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration.Stem cells international · 2018Review
- Coming to terms with tissue engineering and regenerative medicine in the lung.American journal of physiology. Lung cellular and molecular physiology · 2015Review
- Bioreactor-Based Tumor Tissue Engineering.Acta naturaeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
rationaleMuch recent interest in lung bioengineering by pulmonary investigators, industry and the organ transplant field has seen a rapid growth of bioreactor development ranging from the microfluidic scale to the human-sized whole lung systems. A comprehension of the findings from these models is needed to provide the basis for further bioreactor development.
objectiveThe goal was to comprehensively review the current state of bioreactor development for the lung.
methodsA search using PubMed was done for published, peer-reviewed papers using the keywords "lung" AND "bioreactor" or "bioengineering" or "tissue engineering" or "ex vivo perfusion". MAIN
resultsMany new bioreactors ranging from the microfluidic scale to the human-sized whole lung systems have been developed by both academic and commercial entities. Microfluidic, lung-mimic and lung slice cultures have the advantages of cost-efficiency and high throughput analyses ideal for pharmaceutical and toxicity studies. Perfused/ventilated rodent whole lung systems can be adapted for mid-throughput studies of lung stem/progenitor cell development, cell behavior, understanding and treating lung injury and for preliminary work that can be translated to human lung bioengineering. Human-sized ex vivo whole lung bioreactors incorporating perfusion and ventilation are amenable to automation and have been used for whole lung decellularization and recellularization. Clinical scale ex vivo lung perfusion systems have been developed for lung preservation and reconditioning and are currently being evaluated in clinical trials.
conclusionsSignificant advances in bioreactors for lung engineering have been made at both the microfluidic and the macro scale. The most advanced are closed systems that incorporate pressure-controlled perfusion and ventilation and are amenable to automation. Ex vivo lung perfusion systems have advanced to clinical trials for lung preservation and reconditioning. The biggest challenges that lie ahead for lung bioengineering can only be overcome by future advances in technology that solve the problems of cell production and tissue incorporation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.